Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

GSK: Potential Profits from Rare Diseases

February 10, 2010

Analysis of:GSK launches new specialist unit to research and develop medicines for rare diseases | www.pipelinereview.com

GSK announced a unit dedicated to development and commercialization of medicines for rare diseases. The rationale was more products of value, improved R&D return, and higher probabilities of success. Since 1983 FDA has granted 353 orphan drug approvals; 19 have achieved blockbuster status. Good science and good luck are required. Profits result from high prices and indication expansion but high pricing may threaten orphan drug legislation and prevent its expansion for personalized medicine.

Will the Mass. plan for Global Payments influence the quality of M.D. care?

July 23, 2009

Analysis of:Mass. Panel Backs Radical Shift in Health Payment | www.nytimes.com

Despite the Mass. scheme that all have health insurance, costs have risen at 6-9%/yr. To rein in health care costs, a high level commission suggests moving from Fee for Service to a Global Payment System that would compensate physicians for the care of patients on a periodic basis. Capitation reduces health care utilization but lack of standard definitions and measurements will impede assessments of any impact on quality. Less may be more but data are needed to answer this critical question.

Page : 11 to 2 of 2

Subscribe to Updates

By RSS